If You’ve Had a Stent, Check Your Waist

Dr Edward Leatham
Dec 19, 2025
5 min read

Updated: Apr 21

An article written by Dr Edward Leatham, Consultant Cardiologist

When a coronary stent is implanted, the immediate problem—an obstructed artery—is treated. Blood flow improves, symptoms often settle, and the procedure is labelled a success. But a stent treats a local narrowing, not the systemic biology that caused it. For some patients, that biology increases the risk of the artery narrowing again—a process known as in-stent restenosis (ISR).

One of the most important and overlooked contributors to ISR is metabolic health, particularly insulin resistance driven by visceral fat.

In-stent restenosis: a biological response, not a technical failure

ISR is not simply scar tissue. It represents an exaggerated vascular healing response to arterial injury, characterised by:

Endothelial dysfunction
Inflammation
Migration and proliferation of vascular smooth muscle cells
Extracellular matrix deposition

Despite major advances in drug-eluting stent (DES) technology, ISR still occurs—especially in certain biological states¹².

One group has consistently higher risk across all stent eras: patients with diabetes³^,⁴.

Diabetes and ISR: a consistent association

Large registries and pathological studies show that patients with diabetes have:

Higher rates of ISR
Greater neointimal hyperplasia
Increased need for repeat revascularisation

Classic intravascular ultrasound studies demonstrated that the excess restenosis seen in diabetes is due to exaggerated intimal growth, rather than stent under-expansion or recoil⁵.

Importantly, this increased risk persists even with modern DES, indicating that diabetes reflects an underlying biological driver rather than a stent-related issue⁶.

Insulin resistance: the problem often starts earlier

Diabetes is the visible end-stage. The process usually begins years earlier with insulin resistance and compensatory hyperinsulinaemia.

This matters because insulin is not just a glucose-lowering hormone—it is also a growth and repair signal within the vascular wall.

Clinical studies have shown that:

Higher fasting insulin levels are associated with ISR
Insulin resistance (measured by HOMA-IR) independently predicts restenosis after coronary stenting, even in non-diabetic patients⁷
Patients who develop ISR after DES implantation have significantly higher insulin resistance indices than those who do not⁸

These findings suggest that the artery is responding to injury in a pro-proliferative metabolic environment.

Why insulin resistance promotes restenosis

ISR is driven largely by vascular smooth muscle cell (VSMC) behaviour. Insulin resistance and hyperinsulinaemia amplify this process by:

Stimulating VSMC proliferation and migration
Reducing nitric oxide bioavailability
Promoting inflammation and oxidative stress
Impairing normal endothelial repair

Experimental work supports causality: animal models lacking insulin receptors on vascular smooth muscle cells develop less intimal hyperplasia after vascular injury, directly implicating insulin signalling in restenosis biology⁹.

Waist size reveals the real risk: visceral fat

Many patients with insulin resistance do not appear “obese” by BMI standards. The key issue is where fat is stored.

Visceral adipose tissue (VAT)—fat stored deep around the organs—is:

Highly metabolically active
Strongly linked to insulin resistance
Pro-inflammatory
Associated with endothelial dysfunction and accelerated atherosclerosis¹⁰

A simple screening tool is waist-to-height ratio:

Waist circumference ÷ height A ratio >0.5 suggests excess visceral fat¹¹

For patients with a history of stenting, this measurement provides critical information that cholesterol and glucose tests may miss.

Confirmed visceral fat reframes risk after stenting

When imaging (CT, DEXA, MRI) or consistent anthropometric data confirm high VAT, several things become likely:

Insulin resistance is present
Insulin levels are often elevated despite “normal” glucose
The vascular system is exposed to a pro-healing, pro-proliferative environment

This helps explain why some patients experience ISR or progressive coronary disease despite optimal procedural results and guideline-based therapy.

Why GLP-1 mimetics are relevant after a stent

GLP-1 receptor agonists are often discussed as weight-loss drugs. In cardiovascular medicine, that framing is incomplete.

GLP-1 mimetics:

Preferentially reduce visceral fat
Improve insulin sensitivity
Lower circulating insulin levels
Improve endothelial function
Reduce systemic inflammation
Reduce major adverse cardiovascular events in large outcome trials^¹,²,¹³

Although trials have not been designed specifically with ISR as a primary endpoint, the biological rationale is strong: reducing visceral fat and insulin resistance addresses the upstream drivers of restenosis.

This mirrors earlier preventive strategies—such as statins—where mechanistic benefit preceded formal ISR-specific trial endpoints.

What this means for patients who’ve had a stent

If you have had a coronary stent:

Measure your waist
Divide it by your height
If the result is >0.5, ask what this means for your heart

If visceral fat is confirmed, management should extend beyond antiplatelets and cholesterol lowering. Alongside lifestyle change, targeting insulin resistance and VAT—including consideration of GLP-1 therapy—may reduce future risk.

The key message

A stent treats an artery, not metabolism
Diabetes increases restenosis risk—but insulin resistance comes first
Visceral fat is a major driver and is often hidden
Waist-to-height ratio is a powerful, simple screening tool
In selected patients, GLP-1 mimetics represent preventive cardiovascular therapy, not cosmetic weight loss

If you’ve had a stent, checking your waist may be one of the most important follow-up steps you take.

References

Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials. Circulation. 2007;115:2344–2351.
Mehran R, Dangas G, Abizaid AS, et al. Angiographic patterns of in-stent restenosis. Circulation. 1999;100:1872–1878.
Kip KE, Faxon DP, Detre KM, et al. Coronary angioplasty in diabetic patients. Circulation. 1996;94:1818–1825.
Paramasivam G, Devasia T, Rao MS. In-stent restenosis in diabetes mellitus. Turk Kardiyol Dern Ars. 2020;48:156–164.
Kornowski R, Mintz GS, Kent KM, et al. Increased restenosis in diabetes is due to exaggerated intimal hyperplasia. Circulation. 1997;95:1366–1369.
Yahagi K, Kolodgie FD, Otsuka F, et al. Pathophysiology of restenosis. J Am Coll Cardiol. 2016;68:1556–1571.
Nishio K, Shigemitsu M, Kusuyama T, et al. Insulin resistance as a predictor for restenosis after coronary stenting. Int J Cardiol. 2005;103:128–134.
Zhao LP, Xu WT, Wang L, et al. Influence of insulin resistance on in-stent restenosis after DES implantation. Coron Artery Dis. 2015;26:5–10.
Rask-Madsen C, Li Q, Freund B, et al. Loss of insulin signaling in vascular smooth muscle accelerates injury-induced intimal hyperplasia. Nat Med. 2010;16:746–752.
Després JP. Body fat distribution and risk of cardiovascular disease. Circulation. 2012;126:1301–1313.
Ashwell M, Gibson S. Waist-to-height ratio as an early health risk indicator. Nutr Bull. 2016;41:70–80.
Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311–322.
Wilding JPH, Batterham RL, Calanna S, et al. Semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384:989–1002.